The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology – Multiple Myeloma. V.1.2012. http://vvrww.nccn.org. Accessed February 19, 2012.
2.
ZonderJ.A.CrowleyJ.HusseinM.A.Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized South-west Oncology Group trial (S0232). Blood.2010; 116(26): 5838–5841.
3.
GayF.HaymanS.R.LacyM.Q.Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood.2010; 115(7): 1343–1350.
4.
RajkumarS.V.JacobusS.CallanderN.S.Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol.2010; 11(1): 29–37.
5.
RajkumarS.V.HaymanS.R.LacyM.Q.Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood.2005; 106(13): 4050–4053.
6.
KleinU.NebenK.HielscherT.HeibC.HoA.D.GoldschmidtH.Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol.2011; 90(4): 429–439.
7.
DimopoulosM.AlegreA.StadmauerE.A.The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer.2010; 116(16): 3807–3814.
8.
ChenC.ReeceD.SiegelD.Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol.2009; 146(2): 164–170.
9.
DimopoulosM.SpencerA.AttalM.Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med.2007; 357(21): 2123–2132.
10.
WeberD.M.ChenC.NiesvizkyR.Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med.2007; 357(21): 2133–2142.
11.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology – Antiemesis. V.1.2012. http://www.nccn.org. Accessed February 21, 2012.
12.
RoilaF.HerrstedtJ.AaproM.Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol.2010; 21(suppl 5): 232–243.
13.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology – Myeloid Growth Factors. V.1.2011. http://www.nccn.org. Accessed February 21, 2012.
14.
PalumboA.RajkumarS.V.DimopoulosM.A.Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia.2008; 22(2): 414–423.
